Roche supports Sidra Medicine’s global DMD exchange, spotlighting Qatar as a gene therapy hub

Doha, Qatar:Roche Pharmaceuticals, through its local representative Ebn Sina Medical, a fully owned subsidiary of Aamal Company Q.P.S.C will co organi...

Doha, Qatar: Roche Pharmaceuticals, through its local representative Ebn Sina Medical, a fully owned subsidiary of Aamal Company Q.P.S.C will co-organise the Duchenne Muscular Dystrophy (DMD) Peer-to-Peer Exchange 2025 at Sidra Medicine.

The high-level event convened 25 leading neurologists from 9 countries across the world who met in Qatar from to share best practices and learn from Sidra Medicine’s world-class rare disease programme.

Sidra Medicine, a women’s and children’s hospital in Qatar, established a dedicated Gene Therapy Centre in early 2025, which solidifies Sidra Medicine’s position as a regional leader in gene therapy and Qatar as an emerging hub for innovative and pioneering pediatric treatment protocols.

The Global DMD Exchange initiative underscores Roche’s commitment to advancing science and supporting the global medical community. The preceptorship provides a vital platform for physicians to gain direct insights from a centre of excellence that is actively implementing advanced therapies for DMD.

“At Roche, we are deeply committed to improving the lives of patients with rare diseases, which includes supporting the independent exchange of cutting-edge science,” said Roche’s Gulf Cluster Head, Dr Ahmed Tawfik.